FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2403024681> ?p ?o ?g. }

• W2403024681 endingPage "e0155711" @default.
• W2403024681 startingPage "e0155711" @default.
• W2403024681 abstract "Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are required in order to overcome innate and acquired resistance to these drugs and thus expand the array of cancers that could benefit from them. We show that human cancer cell lines which respond poorly to ABT-888 (a PARPi), become sensitive to it when co-treated with vorinostat (a histone deacetylase inhibitor (HDACi)). Vorinostat also sensitized PARPis insensitive cancer cell lines to 6-thioguanine (6-TG)-a drug that targets PARPis sensitive cells. The sensitizing effect of vorinostat was associated with increased phosphorylation of eukaryotic initiation factor (eIF) 2α which in and of itself increases the sensitivity of cancer cells to ABT-888. Importantly, these drug combinations did not affect survival of normal fibroblasts and breast cells, and significantly increased the inhibition of xenograft tumor growth relative to each drug alone, without affecting the mice weight or their liver and kidney function. Our results show that combination of vorinostat and ABT-888 could potentially prove useful for treatment of cancer with innate resistance to PARPis due to active HRR machinery, while the combination of vorinostat and 6-TG could potentially overcome innate or acquired resistance to PARPis due to secondary or reversal BRCA mutations, to decreased PARP-1 level or to increased expression of multiple drug resistant proteins. Importantly, drugs which increase phosphorylation of eIF2α may mimic the sensitizing effect of vorinostat on cellular response to PARPis or to 6-TG, without activating all of its downstream effectors." @default.
• W2403024681 created "2016-06-24" @default.
• W2403024681 creator A5006094460 @default.
• W2403024681 creator A5006711579 @default.
• W2403024681 creator A5007154598 @default.
• W2403024681 creator A5007588773 @default.
• W2403024681 creator A5018466923 @default.
• W2403024681 creator A5021680343 @default.
• W2403024681 creator A5023107814 @default.
• W2403024681 creator A5028805587 @default.
• W2403024681 creator A5042820673 @default.
• W2403024681 creator A5044249462 @default.
• W2403024681 creator A5050824803 @default.
• W2403024681 creator A5057214962 @default.
• W2403024681 creator A5065980115 @default.
• W2403024681 creator A5069717632 @default.
• W2403024681 creator A5071994598 @default.
• W2403024681 creator A5073066369 @default.
• W2403024681 creator A5082558562 @default.
• W2403024681 date "2016-05-19" @default.
• W2403024681 modified "2023-10-13" @default.
• W2403024681 title "Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations" @default.
• W2403024681 cites W137915467 @default.
• W2403024681 cites W1550622700 @default.
• W2403024681 cites W1808356505 @default.
• W2403024681 cites W1836334516 @default.
• W2403024681 cites W1966248219 @default.
• W2403024681 cites W1973268287 @default.
• W2403024681 cites W1982805924 @default.
• W2403024681 cites W1987979989 @default.
• W2403024681 cites W1989006164 @default.
• W2403024681 cites W1991590577 @default.
• W2403024681 cites W1993043513 @default.
• W2403024681 cites W2002228720 @default.
• W2403024681 cites W2005890320 @default.
• W2403024681 cites W2013514037 @default.
• W2403024681 cites W2032183631 @default.
• W2403024681 cites W2045617609 @default.
• W2403024681 cites W2046451284 @default.
• W2403024681 cites W2047119008 @default.
• W2403024681 cites W2057689058 @default.
• W2403024681 cites W2060247906 @default.
• W2403024681 cites W2074446011 @default.
• W2403024681 cites W2077399723 @default.
• W2403024681 cites W2079345935 @default.
• W2403024681 cites W2086038769 @default.
• W2403024681 cites W2089190709 @default.
• W2403024681 cites W2090031006 @default.
• W2403024681 cites W2096439168 @default.
• W2403024681 cites W2100462151 @default.
• W2403024681 cites W2109899028 @default.
• W2403024681 cites W2111884823 @default.
• W2403024681 cites W2116735990 @default.
• W2403024681 cites W2127571330 @default.
• W2403024681 cites W2131670056 @default.
• W2403024681 cites W2140513457 @default.
• W2403024681 cites W2141855935 @default.
• W2403024681 cites W2145879583 @default.
• W2403024681 cites W2146320180 @default.
• W2403024681 cites W2157899948 @default.
• W2403024681 cites W2159729748 @default.
• W2403024681 cites W2162157249 @default.
• W2403024681 doi "https://doi.org/10.1371/journal.pone.0155711" @default.
• W2403024681 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4873128" @default.
• W2403024681 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27196668" @default.
• W2403024681 hasPublicationYear "2016" @default.
• W2403024681 type Work @default.
• W2403024681 sameAs 2403024681 @default.
• W2403024681 citedByCount "17" @default.
• W2403024681 countsByYear W24030246812016 @default.
• W2403024681 countsByYear W24030246812017 @default.
• W2403024681 countsByYear W24030246812018 @default.
• W2403024681 countsByYear W24030246812020 @default.
• W2403024681 countsByYear W24030246812021 @default.
• W2403024681 countsByYear W24030246812022 @default.
• W2403024681 crossrefType "journal-article" @default.
• W2403024681 hasAuthorship W2403024681A5006094460 @default.
• W2403024681 hasAuthorship W2403024681A5006711579 @default.
• W2403024681 hasAuthorship W2403024681A5007154598 @default.
• W2403024681 hasAuthorship W2403024681A5007588773 @default.
• W2403024681 hasAuthorship W2403024681A5018466923 @default.
• W2403024681 hasAuthorship W2403024681A5021680343 @default.
• W2403024681 hasAuthorship W2403024681A5023107814 @default.
• W2403024681 hasAuthorship W2403024681A5028805587 @default.
• W2403024681 hasAuthorship W2403024681A5042820673 @default.
• W2403024681 hasAuthorship W2403024681A5044249462 @default.
• W2403024681 hasAuthorship W2403024681A5050824803 @default.
• W2403024681 hasAuthorship W2403024681A5057214962 @default.
• W2403024681 hasAuthorship W2403024681A5065980115 @default.
• W2403024681 hasAuthorship W2403024681A5069717632 @default.
• W2403024681 hasAuthorship W2403024681A5071994598 @default.
• W2403024681 hasAuthorship W2403024681A5073066369 @default.
• W2403024681 hasAuthorship W2403024681A5082558562 @default.
• W2403024681 hasBestOaLocation W24030246811 @default.
• W2403024681 hasConcept C104317684 @default.
• W2403024681 hasConcept C121608353 @default.
• W2403024681 hasConcept C182979987 @default.
• W2403024681 hasConcept C2776262904 @default.

• next